2 projects

OPEN LABEL RANDOMIZED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF PLASMA THERAPY FROM RECOVERE...

In December 2019, the Wuhan Municipal Health Committee identified an outbreak of viral pneumonia cases of unknown cause. Coronavirus RNA was quickly identified in some of these patients. This novel coronavirus has been designated SARS-CoV-2, and the disease caused by this virus has been designated COVID-19. Currently there are no approved therapeutic agents available for coronaviruses. The purpose of this trial is to provide substantial evidence on the efficacy and safety of the treatment of selected COVID-19 patients with plasma obtained from convalescent COVID-19 patients ('PLASMA').

Innovative end-to-end solution for respiratory diseases detection and genotyping

Our innovative end-to-end solution for respiratory diseases detection and genotyping is composed of 3 main compoenets as follows: First, we want, through a multiplex qPCR assay, to target and differentiate in priority COVID-19, SARS, H5N1, H1N1 (devastating diseases) from seasonal flu (under control). Second, we propose to develop an NGS and SANGER assay for the following Intended uses: Respiratory diseases Genotyping, Screening, Monitoring, Quasispecies identification, Epidemiological studies. Third, we target to establish a large COVID-19 and SARS worldwide database , compare patient ...

export results as excel

MESR FNR University of Luxembourg LIST LISER LIH